Targeted amplification and MinION nanopore sequencing of key azole and echinocandin resistance determinants of clinically relevant Candida spp. from blood culture bottles. (1st September 2021)

• Record Type: Journal Article
• Authors: Chew, K.L.; Octavia, S.; Jureen, R.; Lin, R.T.P.; Teo, J.W.P.
• Is Part Of: Letters in applied microbiology. Volume 73:Number 3(2021)
• Page Start: 286
• Page End: 293
• Publication Date: 2021-09-01
• Subjects: candidaemia -- MinION nanopore sequencing -- antifungal resistance -- ERG11 -- ERG3 -- FKS; Microbiology -- Periodicals; 660.62
• DOI: 10.1111/lam.13516
• Languages: English
• ISSNs: 0266-8254

Abstract

Abstract: The objective of the study was to evaluate the use of targeted multiplex Nanopore MinION amplicon re‐sequencing of key Candida spp. from blood culture bottles to identify azole and echinocandin resistance associated SNPs. Targeted PCR amplification of azole ( ERG11 and ERG3 ) and echinocandin (FKS) resistance‐associated loci was performed on positive blood culture media. Sequencing was performed using MinION nanopore device with R9.4.1 Flow Cells. Twenty‐eight spiked blood cultures (ATCC strains and clinical isolates) and 12 prospectively collected positive blood cultures with candidaemia were included. Isolate species included Candida albicans, Candida glabrata, Candida krusei, Candida parapsilosis, Candida tropicalis and Candida auris . SNPs that were identified on ERG and FKS genes using Snippy tool and CLC Genomic Workbench were correlated with phenotypic testing by broth microdilution (YeastOne™ Sensititre). Illumina whole‐genome‐sequencing and Sanger‐sequencing were also performed as confirmatory testing of the mutations identified from nanopore sequencing data. There was a perfect agreement of the resistance‐associated mutations detected by MinION‐nanopore‐sequencing compared to phenotypic testing for acquired resistance (16 with azole resistance; 3 with echinocandin resistance), and perfect concordance of the nanopore sequence mutations to Illumina and Sanger data. Mutations with no known association with phenotypic drug resistance and novel mutations were also detected.